Brochure / Flyer
Molecular Characterization of Biopharmaceuticals
Explore our Physico-chemical Characterization techniques in characterizing biopharmaceuticals for drug development, including proteins, antibodies, vaccines, and nucleic acid-based drugs using High Resolution Mass Spectrometry (HRMS), Liquid Chromatography (LC), Electrophoretic Mobility (EM)
Integrated Biosimilar Development Solutions
Offering integrated end-to-end Biosimilar Development Solutions for Peptides, Oligonucleotides, Insulin & Analogs, Fusion Proteins & Recombinant Proteins, mAbs, ADCs
Veeda Biopharma's ZipChip Solutions for Advanced Biopharmaceutical Analysis
Explore Veeda Biopharma’s collaboration with Biobeams and 908 devices for offering first-of-its-kind services on the ZipChip platform. ZipChip is a sophisticated platform that enables highly advanced and efficient analysis, specifically designed to cater to the intricate nature of Peptides, Antibodies, Metabolites, and Oligonucleotides.
Our Infrastructure for Biopharma Services
Discover how Veeda Biopharma leverages its state-of-the-art infrastructure to accelerate development programs across diverse biopharmaceutical solutions such as Analytics & Characterization, Bioprocess Development, Discovery Biology, and Clinical Bioanalysis.
Navigating NCE Development
Explore Veeda's Integrated NCE Clinical Development & Bioanalytical Solutions for global Pharmaceutical and Bio-Pharmaceutical Companies.
Olaparib - An Overview of PARP Inhibitors and Clinical Trials
Learn more about Veeda's expertise in designing efficient protocols, optimizing patient recruitment, ensuring regulatory compliance, and maximizing the potential of Olaparib's clinical data. We aim to collaborate with global Pharma and Biopharma companies to accelerate drug development, improve patient outcomes, and shape the future of Oncology.
Late Phase Clinical Trial Capabilities
Explore the full range of late-phase clinical trial capabilities, from phase II to phase IV, in the fields of Oncology, Immunology, Respiratory, Hematology, Central nervous system(CNS) and Infectious diseases, delivering groundbreaking insights for novel treatments and enhanced patient outcomes.
Phase I Trial Capabilities
Discover our Phase I Trial Capabilities, specializing in first-in-human studies, early-phase clinical trials, and vaccine studies, pioneering the exploration of new medical interventions and paving the way for future advancements in healthcare.
Oncology Clinical Trial Capabilities
Discover our comprehensive Oncology Clinical Trial Capabilities, dedicated to advancing the field of cancer research through cutting-edge studies focused on Breast Cancer, Prostate Cancer, Ovarian Cancer, Multiple Myeloma, and Small Cell Lung Cancer, offering hope and innovative treatments for patients worldwide.
Infectious Diseases Drug-development Solutions
Experience a transformative approach to Infectious Disease Drug-development Solutions, integrating ELISPOT studies, COVID-19 research, Polio vaccine studies, and pioneering investigations into blood and skin infections, driving the discovery of innovative treatments to combat complex infectious diseases and promoting global well-being.
Veeda Group - Integrated Drug-development Services
Veeda provides a comprehensive range of services covering pre-clinical studies, Phase I to Phase IV clinical trials, bioavailability and bioequivalence studies, as well as bioanalytical services for both small and large molecules. With a commitment to scientific excellence and regulatory compliance, we deliver reliable data and insights to drive successful drug development.
From Insulins to GLP-1 Receptors: Preparing for the Next Wave of Off-Patent Molecules
Veeda Group has a track record of supporting the development of key diabetic drugs, including Insulin, Liraglutide, Semaglutide, and Sitagliptin. As a trusted partner having a diverse portfolio of 12 Insulins, we deliver comprehensive solutions for endocrinology drug development
Inhalation Drugs Nearing Patent Expiry
Integrated Services Spanning the Full Spectrum of Drug Development Stages
Accelerating Complex Drug Development through the 505(b)(2) Pathway
Injectable Drug Development Support
Complete Solutions for Injectable Drugs Nearing Patent Expiry: Ensuring Seamless Development & Market Readiness
Peptide Analysis
Employing a Comprehensive Array of Techniques and Methods for the Accurate Quantification and Analysis of Peptides
Streamlining Biotherapeutic Development: Analytics and Characterization Solutions
Preferred solution partner for physico-chemical, structural characterization and analytical CMC support for broad range of biotherapeutics ranging from peptides, oligos, recombinant-conjugated-fusion protein, monoclonal antibodies (mAbs), bispecific, antibody (Ab) fragments, antibody-drug conjugates to biopolymers.
Accelerating Biopharma Development: Customized Clinical Bioanalysis Solutions
Offering services to perform Pharmacokinetics, Pharmacodynamics, immunogenicity testing, vaccine sciences and biomarker assays for the development of biotherapeutics with Good Clinical Laboratory Practice (GCLP) compliance.
Biotherapeutic Process Development Solutions
The process development at Biopharma Division of Veeda is equipped for expression and purification of heterologous proteins in microbial and mammalian cells (CHO; HEK) for therapeutic and non-therapeutic proteins with process development and scale-up at 2 L and 5 L bioreactors.
Biopharma Solutions: Discovery Biology
Discovery Biology at Veeda Biopharma division, with its Assay Biology and ADMET/ DMPK solutions offers a large suite of In vitro assays to support your stand-alone research needs or integrated solutions.
Integrated Solutions for Generic & Novel GLP-1 Receptor Agonists: Spanning Preclinical to Clinical Development
Veeda offers integrated solutions for the development of innovative and generic GLP-1 (Glucagon-Like Peptide-1) receptor agonists, covering all stages from meticulous preclinical assessments to advanced clinical trials.
Enhancing Chiral Bioanalysis with Supercritical Fluid Chromatography for NCE molecules
Dr. Abhishek Gandhi, Mr. Jayrajsinh Chudasama, Mr. Kishor Gohil, Dr. Tulsidas Mishra, Ms. Swati Guttikar, Rahmanzadeh Gholamreza, Winter Serge
Event: EBF 2023
Location: Barcelona
Method Development & Validation for Ferric Carboxymaltose Formulation
A Novel Approach for Quantitation of Total Iron and Transferrin Bound Iron in Human serum samples by using ICP-OES
Dr. Pritesh Contractor, Dr. Shanti S Yadav, Dr. Ajay Gupta. Ms. Swati Guttikar, Dr. E. Venu Madhav
Event: APA-2020
Location: Ahmedabad
Method Development & Validation of ISDN and its Metabolites
Sensitive, Reproducible & Simultaneous Bioanalytical method of ISDN and its Metabolites in Human Matrix samples for PK Analysis
Ms. Swati Guttikar, Mr. Jayrajsinh Chudasama, Mr. Vipul Chauhan
Event: WRIB 2023
Location : United States
